Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poziotinib as a Clinically Active Inhibitor of EGFR and HER2 exon 20 mutations

A new TKI on horizon for metastatic NSCLC
27 Apr 2018
Lung and other thoracic tumours;  Translational research;  Anticancer agents & Biologic therapy

A group of researchers led by John V. Heymach of the Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA reported in the Nature Medicine the results from the study that identifies poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations in metastatic non-small cell lung cancer (NSCLC). The findings illuminate the molecular features of tyrosine kinase inhibitors (TKIs) that may circumvent the steric changes induced by these mutations.

The authors wrote in the study background that although most activating mutations of epidermal growth factor receptor (EGFR)-mutant NSCLCs are sensitive to available EGFR TKIs, a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy.

The study team included the researchers from the University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University of Colorado Cancer Center, Yale University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and New York University Langone Medical Center.

The investigators used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modelling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors. Owing to its small size and flexibility, poziotinib can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants.

Furthermore, poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC.

In a phase II trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%.

This work was supported by multiple grants. The clinical study was supported by Spectrum Pharmaceuticals.

Poziotinib was discovered at Hanmi Pharmaceutical in South Korea. In August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals. 


Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine, Published online 23 April 2018. doi:10.1038/s41591-018-0007-9

Last update: 27 Apr 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.